Document
type: Class

Lupus
type: Journal
publication venue for: Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis
type: Entity
type: Thing
type: Document
type: Continuant
type: Generically Dependent Continuant
type: Periodical
type: Collection
type: Information Content Entity

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

RDF description of Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis - http://orbis.uaslp.mx/vivo/individual/scopus6470
rights: termsOfUse
date: 2026-08-24T21:50:59
publisher: vivo
type: Document

Article
type: Class

Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis
e iscopus: 2-s2.0-85086598245
crisid: 6471
most specific type: Article
origen: scopus
related by: authorship_42063
type: Continuant
has publication venue: Lupus
pmid: 32539658
related by: authorship_42059
related by: authorship_42062
type: Document
related by: authorship_42060
type: Entity
most specific type: Document
type: Generically Dependent Continuant
issue: 9
abstract: Background: Mycophenolic acid (MPA) is an effective oral immunosuppressive drug used to treat lupus nephritis (LN), which exhibits large pharmacokinetic variability. This study aimed to characterize MPA pharmacokinetic behaviour in Mexican LN patients and to develop a population pharmacokinetic model which identified factors that influence MPA pharmacokinetic variability. Methods: Blood samples from LN patients treated with mycophenolate mofetil (MMF) were collected pre dose and up to six hours post dose. MPA concentrations were determined by a validated ultra-performance liquid chromatography tandem mass spectrometry technique. Patients were genotyped for polymorphisms in enzymes (UGT1A8, 1A9 and 2B7) and transporters (ABCC2 and SLCO1B3). The anthropometric, clinical, genetic and co-medication characteristics of each patient were considered as potential covariates to explain the variability. Results: A total of 294 MPA concentrations from 40 LN patients were included in the development of the model. The data were analysed using NONMEM software and were best described by a two-compartment linear model. MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h−1 and 20.3 L/h, respectively. Creatinine clearance and prednisone co-administration proved to have influence on clearance, while body weight influenced Vc. The model was internally validated, proving to be stable. MMF dosing guidelines were obtained through stochastic simulations performed with the final model. Conclusions: This is the first MPA population pharmacokinetic model to have found that co-administration of prednisone results in a considerable increase on clearance. Therefore, this and the other covariates should be taken into account when prescribing MMF in order to optimize the immunosuppressant therapy in patients with LN. © The Author(s) 2020.
estado: published
type: Article
freetext keyword: immunosuppressant; lupus nephritis; mycophenolic acid (MPA); NONMEM; Population pharmacokinetics glucuronosyltransferase 1A8; glucuronosyltransferase 1A9; glucuronosyltransferase 2B7; multidrug resistance associated protein 2; mycophenolate mofetil; prednisone; solute carrier organic anion transporter 1B3; tacrolimus; adult; anthropometry; area under the curve; Article; blood sampling; body weight; central volume of distribution; clinical article; clinical feature; creatinine clearance; drug blood level; drug clearance; female; gene frequency; human; immunosuppressive treatment; lupus erythematosus nephritis; male; Mexican; pharmacogenetic testing; pharmacogenetics; plasma concentration-time curve; population research; practice guideline; prescription; priority journal; single nucleotide polymorphism; ultra performance liquid chromatography; vital capacity
page end: 1077
chemicalscas: multidrug resistance associated protein 2, 256503-65-8; mycophenolate mofetil, 116680-01-4, 128794-94-5; prednisone, 53-03-2; tacrolimus, 104987-11-3
page start: 1067
related by: authorship_42065
date time value: article date 6471
volume: 29
doi: 10.1177/0961203320931567
type: Information Content Entity
type: Thing
related by: authorship_42061

Information Content Entity
type: Class